Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-007
- Development stage
- Preclinical
- Lead developer
- Vir Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
VIR-007 is a preclinical broadly neutralizing monoclonal antibody (bNAb) being developed by Vir Biotechnology in partnership with the Bill & Melinda Gates Foundation for the treatment and potential functional cure of HIV. The antibody is engineered using Vir's proprietary platform technology, incorporating Fc-region modifications designed to enhance the immune system's T-cell response to the virus. By recognizing and preventing a wide range of HIV variants from infecting cells, VIR-007 aims to inhibit viral replication and spread. The program's clinical goal is to achieve a vaccine-like effect that enables durable, antiretroviral therapy (ART)-free suppression of the virus.
- Other names
- Vir Biotechnology HIV monoclonal antibodyPreclinical HIV antibody candidates
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on VIR-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-007.